How should I treat acute uncomplicated cystitis in a healthy non‑pregnant adult woman, and what are the recommended options for complicated cases?

Treatment of Acute Uncomplicated Cystitis in Healthy Non-Pregnant Adult Women

For acute uncomplicated cystitis in a healthy non-pregnant adult woman, prescribe nitrofurantoin 100 mg orally twice daily for 5 days as the preferred first-line agent, achieving approximately 93% clinical cure with minimal resistance and collateral damage. 1

First-Line Antibiotic Options

Nitrofurantoin (Preferred)

• Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily for 5 days achieves 93% clinical cure and 88% microbiological eradication, with worldwide resistance rates below 1%. 1, 2
• This agent causes minimal disruption of intestinal flora compared with fluoroquinolones or broad-spectrum cephalosporins, thereby reducing the risk of Clostridioides difficile infection and other collateral antimicrobial damage. 1, 2
• Contraindication: Do not use when estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m² because therapeutic urinary concentrations cannot be achieved. 1, 2
• Do not use for suspected pyelonephritis (fever, flank pain, costovertebral angle tenderness). 1, 2

Trimethoprim-Sulfamethoxazole (TMP-SMX)

• TMP-SMX 160/800 mg (one double-strength tablet) orally twice daily for 3 days provides 93% clinical cure and 94% microbiological eradication when the pathogen is susceptible. 1, 2
• Use ONLY when BOTH of the following criteria are met: 1, 2
  • Local E. coli resistance to TMP-SMX is documented to be <20%
  • The patient has NOT received TMP-SMX in the preceding 3 months
• Multiple studies (clinical, in-vitro, and mathematical modeling) consistently identify a 20% resistance threshold above which TMP-SMX should not be used empirically; failure rates rise sharply above this level. 1, 2
• Many regions now report TMP-SMX resistance exceeding 20%, with some areas reaching 78.3% in persistent infections, making verification of local antibiogram data mandatory before selection. 1, 2

Fosfomycin

• Fosfomycin trometamol 3 g as a single oral dose yields approximately 91% clinical cure, maintains therapeutic urinary concentrations for 24–48 hours, and has initial-infection resistance rates around 2.6%. 1, 2
• The single-dose regimen improves adherence compared with 3–7 day courses and causes minimal collateral damage to intestinal flora. 1, 2
• Although bacteriological eradication rates are somewhat lower than TMP-SMX or 3-day fluoroquinolones, overall clinical efficacy is comparable. 1, 2
• Critical limitation: Fosfomycin should NOT be used for suspected pyelonephritis or upper urinary tract infections due to insufficient tissue penetration and lack of efficacy data. 1, 2, 3

Reserve (Second-Line) Agents – Use Only When First-Line Options Fail or Are Contraindicated

Fluoroquinolones

• Ciprofloxacin 250–500 mg orally twice daily for 3 days OR levofloxacin 250–750 mg orally once daily for 3 days should be reserved exclusively for culture-proven resistant pathogens or documented failure of first-line therapy. 1, 2
• The FDA advisory (July 2016) recommends against fluoroquinolone use for uncomplicated UTIs because serious adverse effects (tendon rupture, peripheral neuropathy, CNS toxicity) outweigh benefits. 2
• Global fluoroquinolone resistance is rising, with some regions reporting ciprofloxacin resistance >83.8% in persistent E. coli infections. 2
• Fluoroquinolones cause significant disruption of gut flora, increase the risk of C. difficile infection, and have been linked to increased MRSA infections and greater resistance among gram-negative bacilli. 1, 2

Beta-Lactam Agents

• Amoxicillin-clavulanate, cefdinir, cefaclor, or cefpodoxime for 3–7 days achieve only 89% clinical cure and 82% microbiological eradication, which is significantly inferior to first-line agents. 1, 2
• Beta-lactams are associated with more adverse events and more rapid UTI recurrence due to disturbance of protective peri-urethral and vaginal microbiota. 1, 2, 4
• Amoxicillin or ampicillin alone should NEVER be used because worldwide E. coli resistance exceeds 55–67%. 1, 2
• Use beta-lactams only when all first-line agents are contraindicated due to allergy, intolerance, or documented resistance. 1

Diagnostic Recommendations

When Urine Culture Is NOT Required

• Routine urine culture is unnecessary for otherwise healthy women presenting with typical lower urinary tract symptoms (dysuria, frequency, urgency) in the absence of vaginal discharge. 1, 2
• Routine post-treatment urinalysis or urine cultures are not indicated for asymptomatic patients who have completed therapy successfully. 1, 2

When Urine Culture IS Mandatory

Obtain urine culture and susceptibility testing when ANY of the following occur: 1, 2

• Persistent symptoms after completing the prescribed regimen
• Recurrence of symptoms within 2–4 weeks
• Fever >38°C, flank pain, or costovertebral angle tenderness suggesting pyelonephritis
• Atypical presentation or presence of vaginal discharge
• History of recurrent infections or prior isolation of resistant organisms
• Pregnancy with urinary symptoms

Management of Treatment Failure

If Symptoms Persist or Recur Within 2 Weeks

• Obtain urine culture and susceptibility testing immediately. 1, 2
• Switch to a different antibiotic class for a full 7-day course (not the original short regimen); assume the original pathogen is resistant to the previously used agent. 1, 2
• Reserve fluoroquinolones only for culture-proven resistance. 1, 2

If Fever Persists Beyond 72 Hours

• Perform renal ultrasound or CT imaging to exclude obstructive uropathy, renal calculi, or abscess formation that may require non-antibiotic interventions. 1, 2

Treatment Algorithm (Evidence-Based Decision Steps)

Step 1: Confirm Uncomplicated Cystitis

• Verify absence of fever, flank pain, pregnancy, indwelling catheter, immunosuppression, diabetes, or recent urinary instrumentation. 1, 2

Step 2: Assess Local TMP-SMX Resistance

• If local E. coli resistance is <20% AND the patient has not used TMP-SMX in the past 3 months → prescribe TMP-SMX 160/800 mg twice daily for 3 days. 1, 2
• Hospital antibiograms often over-represent inpatient or complicated isolates and may underestimate susceptibility in community-acquired uncomplicated cystitis; prospective, unbiased surveillance at the local practice level is essential. 1

Step 3: If TMP-SMX Is Unsuitable

• Prescribe nitrofurantoin 100 mg twice daily for 5 days (preferred) OR fosfomycin 3 g single dose based on patient preference and renal function. 1, 2

Step 4: If Symptoms Persist After 2–3 Days or Recur Within 2 Weeks

• Obtain urine culture and adjust therapy accordingly, reserving fluoroquinolones only for cases with documented resistance. 1, 2

Critical Pitfalls to Avoid

• Do NOT treat asymptomatic bacteriuria in non-pregnant, non-catheterized women; this promotes resistance without clinical benefit. 1, 2
• Do NOT use empiric fluoroquinolones as first-line therapy for uncomplicated cystitis because of serious adverse effects and rising resistance. 1, 2
• Do NOT prescribe TMP-SMX without confirming that local resistance is <20%; failure rates increase sharply above this threshold. 1, 2
• Do NOT use nitrofurantoin when eGFR <30 mL/min/1.73 m² or for suspected pyelonephritis. 1, 2
• Do NOT use oral fosfomycin for suspected upper-tract infection or pyelonephritis. 1, 2, 3
• Do NOT repeat the same antibiotic that failed initially; assume resistance and switch to a different mechanism of action. 2

Complicated Cystitis – When Standard Short-Course Therapy Is Inappropriate

Definition of Complicated UTI

Presence of ANY of the following factors makes a UTI "complicated" and requires alternative management: 1, 2

• Fever >38°C, flank pain, or costovertebral angle tenderness (suggests pyelonephritis)
• Pregnancy
• Male sex
• Indwelling urinary catheter
• Urinary obstruction or anatomic abnormalities
• Immunosuppression
• Recent urinary instrumentation
• Diabetes (in some classifications)

Management Approach for Complicated Cases

• Always obtain urine culture and susceptibility testing before initiating therapy. 1, 2
• Extend treatment duration to 7–14 days (instead of 3–5 days). 1, 2
• For suspected pyelonephritis: prescribe ciprofloxacin 500 mg twice daily for 7 days OR levofloxacin 750 mg once daily for 5–7 days, and add an initial intravenous dose of ceftriaxone 1 g if local fluoroquinolone resistance exceeds 10%. 1, 2
• Oral fosfomycin and nitrofurantoin should NOT be used for pyelonephritis because of inadequate tissue penetration. 1, 2